ATG2A

Across TCGA pan-cancer cohorts, ATG2A mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ATG2A data layer compared with 23 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ATG2A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ATG2A expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

CCRCC, PDAC, and HNSC are the cancer types where ATG2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.872	0.620	.002	32	view →
PDAC	OS	Quartile	All	0.431	0.841	.009	25	view →
HNSC	OS	Median	All	0.788	0.616	.021	11	view →
UCEC	DFS	Median	All	0.849	0.957	.021	8	view →
LSCC	DFS	Tertile	III,IV	0.709	1.000	.044	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ATG2A–CCRCC (DFS)

Open the CCRCC breakdown →